Non-Metastatic Prostate Cancer Clinical Trial
Official title:
A Phase I/II Study of ZD1839 (Iressa) Given Concurrently With Radiotherapy in Patients With Non-Metastatic Prostate Cancer
To estimate the safety and tolerability of 250 mg ZD1839 given concurrently with 3D-CRT in patients with non-metastatic prostate cancer
n/a
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04400656 -
PROState Pathway Embedded Comparative Trial
|
||
| Completed |
NCT00673205 -
(Bicalutamide) Casodex vs Placebo in Non-metastatic Early Prostate Cancer
|
Phase 3 | |
| Completed |
NCT00672282 -
Casodex vs Placebo in Non-Metastatic Early Prostate Cancer
|
Phase 3 | |
| Recruiting |
NCT01317043 -
A Trial of Samarium 153 Followed by Salvage Prostatic Fossa 3D-CRT or IMRT Irradiation in High-Risk, Clinically Non-Metastatic Prostate Cancer After Radical Prostatectomy
|
Phase 2 | |
| Completed |
NCT06204302 -
An Observational Study to Learn More About the Use of Androgen Receptor Inhibitors and How They Affect Men With Nonmetastatic Prostate Cancer in Routine Medical Care in the United States
|
||
| Not yet recruiting |
NCT06202248 -
A Study to Assess Alpha DaRT224 for the Treatment of Men With Non-metastatic Locally Recurrent Prostate Cancer
|
N/A | |
| Recruiting |
NCT04049747 -
Comparative Health Research Outcomes of NOvel Surgery in Prostate Cancer
|
N/A | |
| Active, not recruiting |
NCT05617885 -
Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT00657904 -
Bicalutamide (Casodex™) Versus Placebo in Patients With Early Prostate Cancer
|
Phase 3 |